Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Deferred Revenue (2016 - 2018)

Heron Therapeutics' Current Deferred Revenue history spans 4 years, with the latest figure at $14.0 million for Q4 2018.

  • For Q4 2018, Current Deferred Revenue rose 407.06% year-over-year to $14.0 million; the TTM value through Dec 2018 reached $14.0 million, up 407.06%, while the annual FY2018 figure was $14.0 million, 407.06% up from the prior year.
  • Current Deferred Revenue reached $14.0 million in Q4 2018 per HRTX's latest filing, up from $10.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $14.0 million in Q4 2018 to a low of $1.1 million in Q4 2016.
  • Average Current Deferred Revenue over 3 years is $6.2 million, with a median of $5.2 million recorded in 2017.
  • The largest YoY upside for Current Deferred Revenue was 407.06% in 2018 against a maximum downside of 55.21% in 2018.
  • A 3-year view of Current Deferred Revenue shows it stood at $1.1 million in 2016, then surged by 151.41% to $2.8 million in 2017, then skyrocketed by 407.06% to $14.0 million in 2018.
  • Per Business Quant, the three most recent readings for HRTX's Current Deferred Revenue are $14.0 million (Q4 2018), $10.5 million (Q3 2018), and $9.4 million (Q2 2018).